ISIN | LU2207278669 |
---|---|
Valor Number | 114371863 |
Bloomberg Global ID | |
Fund Name | Kieger Impact Healthcare Fund Class R USD Accumulating |
Fund Provider |
Kieger AG
Kieger AG Limmatstrasse 264, CH-8005 Zürich Phone: +41 44 444 18 44 Web: https://kieger.com/ E-Mail: info@kieger.com |
Fund Provider | Kieger AG |
Representative in Switzerland |
ACOLIN Fund Services AG Zürich Phone: +41 44 396 96 96 |
Distributor(s) | |
Asset Class | Equities |
EFC Category | |
Distribution Policy | Accumulation |
Home Country | Luxembourg |
Issuing Condition | The fund does not charge any issuing commission and/or fees (units are issued at the NAV) |
Redemption Condition | The fund does not charge any redemption commission and/or fees (units are redeemed at the NAV) |
Investment Strategy *** | The investment objective of the Sub-Fund is to achieve long term capital growth by principally investing in equities of healthcare and healthcare related companies or issuers worldwide (including Emerging Markets) with a focus on issuers that contribute to the realisation of the healthcare related United Nations Sustainable Development Goals ("SDGs"). No guarantee can be given that the investment objective will be achieved. |
Peculiarities |
Current Price * | 88.70 USD | 21.11.2024 |
---|---|---|
Previous Price * | 87.99 USD | 20.11.2024 |
52 Week High * | 98.37 USD | 28.12.2023 |
52 Week Low * | 86.30 USD | 23.11.2023 |
NAV * | 88.70 USD | 21.11.2024 |
Issue Price * | ||
Redemption Price * | ||
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 80,931,489 | |
Unit/Share Assets *** | 1,775 | |
Trading Information SIX |
YTD Performance | -9.09% |
29.12.2023 - 21.11.2024
29.12.2023 21.11.2024 |
---|---|---|
YTD Performance (in CHF) | -4.21% |
29.12.2023 - 21.11.2024
29.12.2023 21.11.2024 |
1 month | -2.87% |
21.10.2024 - 21.11.2024
21.10.2024 21.11.2024 |
3 months | -6.50% |
21.08.2024 - 21.11.2024
21.08.2024 21.11.2024 |
6 months | -7.71% |
21.05.2024 - 21.11.2024
21.05.2024 21.11.2024 |
1 year | +3.74% |
21.11.2023 - 21.11.2024
21.11.2023 21.11.2024 |
2 years | -11.30% |
06.07.2023 - 21.11.2024
06.07.2023 21.11.2024 |
3 years | - | - |
5 years | - | - |
Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
ResMed Inc | 4.00% | |
---|---|---|
Tandem Diabetes Care Inc | 3.74% | |
Hikma Pharmaceuticals PLC | 3.63% | |
Ambu AS Class B | 3.43% | |
Sandoz Group AG Registered Shares | 3.39% | |
Guardant Health Inc | 3.37% | |
Ionis Pharmaceuticals Inc | 3.34% | |
GSK PLC | 3.34% | |
Natera Inc | 3.32% | |
BioNTech SE ADR | 3.31% | |
Last data update | 30.04.2024 |
TER *** | 2.22% |
---|---|
TER date *** | 30.09.2023 |
Performance Fee *** | |
PTR | |
Max. Management Fee *** | 2.00% |
Ongoing Charges *** | 1.44% |
SRRI ***
|
|
SRRI date *** | 31.10.2024 |
Low Carbon Designation *** | |
---|---|
ESG Rating Overall *** | |
ESG Rating Corporate *** | |
ESG Rating Sovereign *** | |
% AuM H&S Controversies *** |
Avg Carbon Risk Score *** | |
---|---|
Avg Carbon Risk Cat Avg *** | |
% AuM Covered Carbon *** | |
Avg Fossil Fuel Exposure *** | |
Fossil Fuel Cat Avg *** |
Strategy Level 1 *** | |
---|---|
Strategy Level 2 *** | |
Strategy Level 3 *** | |
Exclusions Level 1 *** | |
Exclusions Level 2 *** |